Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs.
The ability of a genetically detoxified mutant of heat labile enterotoxin (LTK63) to act as a mucosal adjuvant following intranasal immunization with recombinant gD2 has previously been reported in mice [Ugozzoli M, O'Hagan DT, Ott GS. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunol 1998;93:563-571.]. In the current studies, these observations were extended to the guinea pig model. Immunized guinea pigs were subsequently challenged intravaginally with HSV-2. Intranasal immunization with gD2 and LTK63 induced a significant reduction in disease severity and a reduction in mortality. However, only intramuscular immunization with a potent adjuvant (MF59) induced protection against the incidence of disease.
Chiron Corporation, Emeryville, CA 94608, USA.
D
D
O'Hagan
C
C
Goldbeck
M
M
Ugozzoli
G
G
Ott
R L
RL
Burke
D000281:Administration, Intranasal; D000818:Animals; D005260:Female; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000401:mortality* / Q000517:prevention & control*; D018258:Herpesvirus 2, Human / Q000276:immunology*; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D014759:Viral Envelope Proteins / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use
D011994:Recombinant Proteins; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C040570:glycoprotein D-herpes simplex virus type 2